Genflow Biosciences Company Description

Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium.

Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion.

The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use.

Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Genflow Biosciences plc

Country	United Kingdom
Founded	2021
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Eric Leire

Contact Details

Address: 6 Heddon Street London, W1B 4BT United Kingdom
Website	genflowbio.com

Stock Details

Ticker Symbol	GENF
Exchange	London Stock Exchange
Fiscal Year	January - December
Reporting Currency	GBP
ISIN Number	GB00BP2C3V08
SIC Code	2836

Key Executives

Name	Position
Dr. Eric Jean Leire M.D., MBA	Founder, Chief Executive Officer and Executive Director
Dr. Cedric Szpirer	Head of CMC